Anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the treatment of neovascular eye diseases, but responses are incomplete in some patients. Recent evidence shows that integrins are involved in the pathogenesis of neovascular age-related macular degeneration and diabetic retinopathy. JP1, derived from an optimized seven-amino-acid fragment of JWA protein, is a polypeptide specifically targeting integrin αVβ3. In this study we evaluated the efficacy of JP1 on laser-induced choroidal neovascularization (CNV) and retinal vascular leakage. CNV mice received a single intravitreal (IVT) injection of JP1 (10, 20, 40 µg) or ranibizumab (RBZ, 10 µg). We showed that JP1 injection dose-dependently inhibited laser-induced CNV; the effect of RBZ was comparable to that of 20 µg JP1; a combined IVT injection of JP1 (20 μg) and RBZ (5 μg) exerted a synergistic effect on CNV. In the 3rd month after streptozotocin injection, diabetic mice receiving IVT injection of JP1 (40 µg) or RBZ (10 µg) once a week for 4 weeks showed significantly suppressed retinal vascular leakage. In both in vivo and in vitro experiments, JP1 counteracted oxidative stress and inflammation via inhibiting ROS/NF-κB signaling in microglial cells, and angiogenesis via modulating MEK1/2-SP1-integrin αVβ3 and TRIM25-SP1-MMP2 axes in vascular endothelial cells. In addition, intraperitoneal injection of JP1 (1, 5 or 10 mg) once every other day for 3 times also dose-dependently inhibited CNV. After intraperitoneal injection of FITC-labeled JP1 (FITC-JP1) or FITC in laser-induced CNV mice, the fluorescence intensity in the CNV lesion was markedly increased in FITC-JP1 group, compared with that in FITC group, confirming that JP1 could penetrate the blood-retinal barrier to target CNV lesion. We conclude that JP1 can be used to design novel CNV-targeting therapeutic agents that may replace current invasive intraocular injections.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Yun JH. Hepatocyte growth factor prevents pericyte loss in diabetic retinopathy. Microvasc Res. 2021;133:104103.
Granstam E, Aurell S, Sjövall K, Paul A. Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting. Graefes Arch Clin Exp Ophthalmol. 2021;259:2085–93.
Cécile D. Epidemiology of age-related macular degeneration. La Rev du praticien. 2017;67:88–91.
Mettu PS, Allingham MJ, Cousins SW. Incomplete response to anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2020;82:100906.
Sun X, Yang S, Zhao J. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Dev Ther. 2016;10:1857–67.
Ehlken C, Jungmann S, Bhringer D, Agostini HT, Pielen A. Switch of anti-VEGF is an option for nonresponders in the treatment of AMD. Eye. 2014;28:538–45.
Tian Y, Zhang F, Qiu Y, Wang S, Li F, Zhao J, et al. Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells. Nat Biomed Eng. 2021;5:968–82.
Wallsh JO, Gallemore RP. Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells. 2021;10:1049.
Pb A, Nam A, Tacma B, Wudunn AD, Lbc A. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol. 2018;63:281–95.
Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol. 2016;35:310–4.
Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88–93.
Ren C, Hui S, Jiang J, Liu Q, Du Y, He M, et al. The effect of CM082, an oral tyrosine kinase inhibitor, on experimental choroidal neovascularization in rats. J Ophthalmol. 2017;2017:6145651.
Kechagia JZ, Ivaska J, Roca-Cusachs P. Integrins as biomechanical sensors of the microenvironment. Nat Rev Mol Cell Biol. 2019;20:1–17.
Hu TT, Vanhove M, Porcu M, Van Hove I, Van Bergen T, Jonckx B, et al. The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Exp Eye Res. 2019;180:43–52.
Umeda N, Shu K, Akiyama H, Zahn G, Campochiaro PA. Suppression and regression of choroidal neovascularization by systemic administration of an α5β1 integrin antagonist. Mol Pharmacol. 2006;69:1820–8.
Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5:273–86.
Nebbioso M, Lambiase A, Cerini A, Limoli PG, La Cava M, Greco A. Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules. Int J Mol Sci. 2019;20:1693.
Askew BC, Furuya T, Edwards DS. Pharmacodynamics and pharmacokinetics of SF0166, a topically administered αvβ3 integrin antagonist, for the treatment of retinal diseases. J Pharmacol Exp Ther. 2018;366:jpet.118.248427.
Cao H, Xia W, Shen Q, Hua L, Jian Y, Li A, et al. Role of JWA in acute promyelocytic leukemia cell differentiation and apoptosis triggered by retinoic acid, 12-tetradecanoylphorbol-13-acetate and arsenic trioxide. Chin Sci Bull. 2002;47:834–8.
Chen Y, Huang Y, Huang Y, Xia X, Zhang J, Zhou Y, et al. JWA suppresses tumor angiogenesis via Sp1-activated matrix metalloproteinase-2 and its prognostic significance in human gastric cancer. Carcinogenesis. 2014;35:442–51.
Cui J, Shu C, Xu J, Chen D, Zhou J. JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin αvβ3 signaling. Theranostics. 2020;10:8036–50.
Lambert V, Lecomte J, Hansen S, Blacher S, Gonzalez M, Struman I, et al. Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nat Protoc. 2013;8:2197–211.
Li L, Zhu M, Wu W, Qin B, Ding D. Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor, suppresses laser-induced CNV in a mouse model of neovascular AMD. J Cell Physiol. 2020;235:1259–73.
Lai K, Gong Y, Zhao W, Li L, Jin C. Triptolide attenuates laser-induced choroidal neovascularization via M2 macrophage in a mouse model. Biomed Pharmacother. 2020;129:110312.
Bergen TV, Hu TT, Etienne I, Reyns GE, Moons L, Feyen J Neutralization of placental growth factor as a novel treatment option in diabetic retinopathy. Exp Eye Res. 2017:S0014483517304505.
Naderi A, Zahed R, Aghajanpour L, Amoli FA, Lashay A. Long term features of diabetic retinopathy in streptozotocin-induced diabetic Wistar rats. Exp Eye Res. 2019;184:213–20.
Indaram M, Ma W, Zhao L, Fariss RN, Rodriguez IR, Wong WT. 7-Ketocholesterol increases retinal microglial migration, activation, and angiogenicity: a potential pathogenic mechanism underlying age-related macular degeneration. Sci Rep. 2015;5:9144.
Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal microglia: just bystander or target for therapy? Prog Retin Eye Res. 2015;45:30–57.
Kinuthia UM, Wolf A, Langmann T. Microglia and inflammatory responses in diabetic retinopathy. Front Immunol. 2020;11:564077.
Yang Y, Liu F, Tang M, Yuan M, Hu A, Zhan Z, et al. Macrophage polarization in experimental and clinical choroidal neovascularization. Sci Rep. 2016;6:30933.
Bretz CA, Divoky V, Prchal J, Kunz E, Simmons AB, Wang H, et al. Erythropoietin signaling increases choroidal macrophages and cytokine expression, and exacerbates choroidal neovascularization. Sci Rep. 2018;8:2161.
Yeo NJY, Chan EJJ, Cheung C. Choroidal neovascularization: mechanisms of endothelial dysfunction. Front Pharmacol. 2019;10:1363.
Kim SY, Kambhampati SP, Bhutto IA, Mcleod DS, Kannan RM. Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model. Exp Eye Res. 2020;203:108391.
Zhao X, Wang R, Xiong J, Yan D, Li A, Wang S, et al. JWA antagonizes paraquat-induced neurotoxicity via activation of Nrf2. Toxicol Lett. 2017;277:32–40.
Datta S, Cano M, Ebrahimi K, Wang L, Handa JT. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017;60:201–18.
Lier J, Streit WJ, Bechmann I. Beyond activation: characterizing microglial functional phenotypes. Cells. 2021;10:2236.
Kim YJ, Park SY, Koh YJ, Lee JH. Anti-neuroinflammatory effects and mechanism of action of Fructus ligustri lucidi extract in BV2 microglia. Plants. 2021;10:688.
Lu J, Tang Y, Farshidpour M, Cheng Y, Zhang G, Jafarnejad SM, et al. JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma. Carcinogenesis. 2013;34:2778–88.
Chen JJ, Ren YL, Shu CJ, Zhang Y, Chen MJ, Xu J, et al. JP3, an antiangiogenic peptide, inhibits growth and metastasis of gastric cancer through TRIM25/SP1/MMP2 axis. J Exp Clin Cancer Res. 2020;39:118.
Capitão M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J Cell Biochem. 2016;117:2443–53.
Hamdan F, Bigdeli Z, Asghari SM, Sadremomtaz A, Balalaie S. Synthesis of modified RGD-based peptides and their in vitro activity. ChemMedChem. 2019;14:282–8.
Semeraro F, Cancarini A, Dell’Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015:1–16.
Arroba AI, Valverde Á. Modulation of microglia in the retina: new insights into diabetic retinopathy. Acta Diabetol. 2017;54:527.
Wang M, Wang X, Zhao L, Ma W, Rodriguez IR, Fariss RN, et al. Macroglia-microglia interactions via TSPO signaling regulates microglial activation in the mouse retina. J Neurosci. 2014;34:3793–806.
Alves CH, Fernandes R, Santiago AR, Ambrósio AF. Microglia contribution to the regulation of the retinal and choroidal vasculature in age-related macular degeneration. Cells. 2020;9:1217.
Zhang T, Ouyang H, Mei X, Lu B, Yu Z, Chen K, et al. Erianin alleviates diabetic retinopathy by reducing retinal inflammation initiated by microglial cells via inhibiting hyperglycemia-mediated ERK1/2-NF-κB signaling pathway. FASEB J. 2019;33:11776–90.
Chen N, Jiang K, Yan GG. Effect of fenofibrate on diabetic retinopathy in rats via SIRT1/NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23:8630–6.
Cai Y, Li W, Tu H, Chen N, Zhong Z, Yan P, et al. Curcumolide reduces diabetic retinal vascular leukostasis and leakage partly via inhibition of the p38MAPK/NF-κ B signaling. Bioorg Med Chem Lett. 2017;27:1835–9.
Popiolek-Barczyk K, Mika J. Targeting the microglial signaling pathways: new insights in the modulation of neuropathic pain. Curr Med Chem. 2016;23:2908–28.
Miao SH, Sun HB, Ye Y, Yang JJ, Shi YW, Lu M, et al. Astrocytic JWA expression is essential to dopaminergic neuron survival in the pathogenesis of Parkinson’s disease. CNS Neurosci Ther. 2014;20:754–62.
Bhatwadekar AD, Kansara V, Luo Q, Ciulla T. Anti-integrin therapy for retinovascular diseases. Expert Opin Investig Drugs. 2020;29:935–45.
Sani S, Messe M, Fuchs Q, Pierrevelcin M, Laquerriere P, Entz-Werle N, et al. Biological relevance of RGD-integrin subtype-specific ligands in cancer. Chembiochem. 2021;22:1151–60.
Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82:100906.
Sheets KG, Jun B, Zhou Y, Zhu M, Petasis NA, Gordon WC, et al. Microglial ramification and redistribution concomitant with the attenuation of choroidal neovascularization by neuroprotectin D1. Mol Vis. 2013;19:1747–59.
Deczkowska A, Amit I, Schwartz M. Microglial immune checkpoint mechanisms. Nat Neurosci. 2018;21:779–86.
Hikage F, Lennikov A, Mukwaya A, Lachota M, Ida Y, Utheim TP, et al. NF-κB activation in retinal microglia is involved in the inflammatory and neovascularization signaling in laser-induced choroidal neovascularization in mice. Exp Cell Res. 2021;403:112581.
Wang R, Zhao X, Xu J, Wen Y, Li A, Lu M, et al. Astrocytic JWA deletion exacerbates dopaminergic neurodegeneration by decreasing glutamate transporters in mice. Cell Death Dis. 2018;9:352.
Kim SY, Kambhampati SP, Bhutto IA, McLeod DS, Lutty GA, Kannan RM. Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model. Exp Eye Res. 2021;203:108391.
Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9:12.
Chu Y, Chen N, Yu H, Mu H, He B, Hua H, et al. Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles. Int J Nanomed. 2017;12:1353–68.
Del Amo EM, Rimpelä AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134–85.
Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370:602–24.
Cai W, Chen Q, Shen T, Yang Q, Hu W, Zhao P, et al. Intravenous anti-VEGF agents with RGD peptide-targeted core cross-linked star (CCS) polymers modified with indocyanine green for imaging and treatment of laser-induced choroidal neovascularization. Biomater Sci. 2020;8:4481–91.
Wang X, Lou N, Eberhardt A, Yang Y, Kusk P, Xu Q, et al. An ocular glymphatic clearance system removes β-amyloid from the rodent eye. Sci Transl Med. 2020;12:eaaw3210.
We would like to thank Kun Ding for technical assistance with the experiments, and to Yong-ke Cao for proofreading of the manuscript. This study is supported by the National Natural Science Foundation of China (Nos. 81970821, 81973156, 81770973, 81870694).
The authors declare no competing interests.
About this article
Cite this article
Xie, Z., Wu, Xj., Cheng, Rw. et al. JP1, a polypeptide specifically targeting integrin αVβ3, ameliorates choroidal neovascularization and diabetic retinopathy in mice. Acta Pharmacol Sin (2022). https://doi.org/10.1038/s41401-022-01005-2
- choroidal neovascularization
- diabetic retinopathy
- oxidative stress